Status:

COMPLETED

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborating Sponsors:

H. Lundbeck A/S

Conditions:

Bipolar I Disorder

Acute Mania

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

This study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar I...

Detailed Description

While the availability of atypical antipsychotics had increased the therapeutic options available, there remains a need for safer and more effective therapies in the treatment of manic and depressive ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (rollover participants from 331-201-00080 \& 331-201-00081 trials)
  • Participants remaining in hospital at the Day 21 visit of trial 331-201-00080 or 331-201-00081 were permitted to enroll in the 331-201-00083 trial at the week 3 visit of the double-blind trial if they were planned to be discharged from the hospital before the week 1 visit of trial 331-201-0083. Participants not discharged by the week 1 visit of trial 331-201-0083 were withdrawn.
  • Participants who, in the opinion of the investigator, could potentially benefit from administration of oral brexpiprazole for the treatment of bipolar I disorder and who completed 3 weeks of post-randomization treatment in Trial 331-201-00080 \& Trial 331-201-00081.
  • Exclusion Criteria (rollover participants from 331-201-00080 \& 331-201-00081 trials)
  • Participants with a major protocol violation during the course of their participation in the double-blind phase 3 trials (331-201-00080 or 331-201-00081).

Exclusion

    Key Trial Info

    Start Date :

    October 24 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 31 2019

    Estimated Enrollment :

    381 Patients enrolled

    Trial Details

    Trial ID

    NCT03287869

    Start Date

    October 24 2017

    End Date

    July 31 2019

    Last Update

    August 17 2020

    Active Locations (73)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 19 (73 locations)

    1

    Woodland International Research Group

    Little Rock, Arkansas, United States, 72211

    2

    Woodland Research Northwest, LLC

    Rogers, Arkansas, United States, 72758

    3

    Citrials Inc.

    Bellflower, California, United States, 90706

    4

    Radiant Research

    Cerritos, California, United States, 90703